Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys
Proteomics International Laboratories (ASX:PIQ) investors are left with "considerable unknowns" after the medical technology business terminated its exclusive license with Sonic Healthcare USA for its PromarkerD kidney disease diagnostic tool, according to a Wednesday note from Euroz Hartleys.
The license was canceled after certain milestones were not met, with the US launch now slated for 2025, targeting alternative pathology labs and service providers, and direct to consumers and patients.
While Proteomics has partners for Europe and other territories for PromarkerD, not commercializing in the US healthcare market, the world's largest, has lost potentially 32 million patients and potential users of the test, the investment firm said.
Euroz Hartleys downgraded Proteomics to hold from speculative buy and lowered the price target to AU$0.73 price target from AU$1.10 on increased uncertainties around the commercialization of PromarkerD in the US.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。